It's sunny and the East Sunshine drug is hitting Merca East 900 million sugar-lowering drugs!

Pharmaceutical network October 10, recently, CDE official website shows that Shandong Langno Pharmaceuticals phosphate sigletin imitation 4 categories of listing applications were accepted.
2019, China's public medical institutions terminal phosphate sigletin tablet sales of more than 900 million yuan, production enterprises only Meshadong.
in February this year, Zhengda Tianqing Pharmaceuticals was approved for the first time, and in August, Guangdong Dongsian Pharmaceuticals became the second generic drug company to be approved.
Up to now, the product has Yangzijiang Pharmaceutical Group Guangzhou Hairui Pharmaceuticals, Chenxin Pharmaceuticals, Stone Pharmaceuticals Group, Ouyi Pharmaceuticals and other 10 enterprises to copy 4 categories of submitted listing applications in the review and approval.
Sigredin phosphate tablets are a powerful, highly selective lipidase-4 (DPP-4) inhibitor, a new oral anti-hyperglycemia drug based on the hormone mechanism of the islet hormone in the intestines to improve blood sugar control in patients with type 2 diabetes.
In recent years, china's public medical institutions terminal sigletin tablet sales (unit: 100 million yuan) Source: Minet China's public medical institutions terminal competition pattern Mi intranet data show that in 2019 China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (China's public medical institutions) terminal sigletin tablet sales of more than 900 million yuan, an increase of 34.89 percent year-on-year, production enterprises only in Mosadong.
source: Mi Net one-click search in February this year, phosphoric acid sigletin tablets are the first to be approved by the pharmaceutical industry, in August, Guangdong Dongsian Pharmaceuticals became the second approved generic pharmaceutical enterprises.
and both enterprises were approved in the imitation 4 categories, as if through consistency evaluation.
Source: Minet MED2.0 China Drug Review Database Up to now, the product Yangzijiang Pharmaceutical Group Guangzhou Hairui Pharmaceuticals, ChenXin Pharmaceuticals, Shi Pharmaceutical Group Oyi Pharmaceuticals and other 10 enterprises to copy 4 categories of submitted listing applications in the review and approval.
.